Literature DB >> 1684057

Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy").

J Sharkey1, D E McBean, P A Kelly.   

Abstract

The effect of the psychomotor stimulant, 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"), upon integrated cerebral function was measured in rats using the quantitative [14C]deoxyglucose autoradiographic technique. Animals were injected with MDMA (20 mg/kg sc) twice daily for 4 days. Fourteen days after the final administration, [3H]-paroxetine binding to 5HT uptake sites was reduced by 89% in membranes prepared from tissue samples of frontal cortex. In the same rats [3H]-paroxetine binding autoradiography revealed heterogeneity in the regional distribution of 5-HT uptake site depletion within neocortex (0-92%) and hippocampus (30-95%). Despite these profound reductions in 5-HT uptake sites no significant alterations were found in glucose utilisation in any area of neocortex examined. However, significant increases in glucose use were found in subregions of the hippocampus, most notably within the pyramidal cell layer of CA2 and CA3 (25-35%). This study provides direct evidence that the loss of 5-HT innervation caused by exposure to MDMA results in lasting functional changes in hippocampus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684057     DOI: 10.1007/bf02316872

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

Authors:  L Sokoloff; M Reivich; C Kennedy; M H Des Rosiers; C S Patlak; K D Pettigrew; O Sakurada; M Shinohara
Journal:  J Neurochem       Date:  1977-05       Impact factor: 5.372

2.  Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate.

Authors:  W Slikker; R R Holson; S F Ali; M G Kolta; M G Paule; A C Scallet; D E McMillan; J R Bailey; J S Hong; F M Scalzo
Journal:  Neurotoxicology       Date:  1989       Impact factor: 4.294

3.  MDA: an agent that produces stimulus effects similar to those of 3,4-DMA, LSD and cocaine.

Authors:  R A Glennon; R Young
Journal:  Eur J Pharmacol       Date:  1984-03-23       Impact factor: 4.432

Review 4.  The background and chemistry of MDMA.

Authors:  A T Shulgin
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

Review 5.  Relation between physiological function and energy metabolism in the central nervous system.

Authors:  L Sokoloff
Journal:  J Neurochem       Date:  1977-07       Impact factor: 5.372

6.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

7.  MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.

Authors:  G Battaglia; S Y Yeh; E B De Souza
Journal:  Pharmacol Biochem Behav       Date:  1988-02       Impact factor: 3.533

8.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.

Authors:  D M Stone; D C Stahl; G R Hanson; J W Gibb
Journal:  Eur J Pharmacol       Date:  1986-08-22       Impact factor: 4.432

9.  Can drugs be used to enhance the psychotherapeutic process?

Authors:  L Grinspoon; J B Bakalar
Journal:  Am J Psychother       Date:  1986-07

10.  Autoradiographic localization of 3H-paroxetine-labeled serotonin uptake sites in rat brain.

Authors:  E B De Souza; B L Kuyatt
Journal:  Synapse       Date:  1987       Impact factor: 2.562

View more
  14 in total

1.  Does recreational ecstasy use cause long-term cognitive problems?

Authors:  P A Kelly
Journal:  West J Med       Date:  2000-08

2.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

3.  Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain.

Authors:  María Izco; Laura Orio; Esther O'Shea; M Isabel Colado
Journal:  Psychopharmacology (Berl)       Date:  2006-10-18       Impact factor: 4.530

4.  A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice.

Authors:  Isabel Escobedo; Esther O'Shea; Laura Orio; Veronica Sanchez; Mireia Segura; Rafael de la Torre; Magi Farre; Alfred Richard Green; Maria Isabel Colado
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

5.  Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.

Authors:  M I Colado; E O'Shea; R Granados; B Esteban; A B Martín; A R Green
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

6.  The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.

Authors:  V Sanchez; J Camarero; B Esteban; M J Peter; A R Green; M I Colado
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

7.  Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain.

Authors:  Paul A T Kelly; Isobel M Ritchie; Linda Quate; Douglas E McBean; Henry J Olverman
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

8.  Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.

Authors:  Brigitta Balogh; Eszter Molnar; Rita Jakus; Linda Quate; Henry J Olverman; Paul A T Kelly; Sandor Kantor; Gyorgy Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.

Authors:  M I Colado; J L Williams; A R Green
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

Review 10.  Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Authors:  A R Green; A J Cross; G M Goodwin
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.